Orbital ATK, Inc.
OA
New York Stock Exchange134.50
USD
+0.01
- -
CIK
0000866121
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Industrials
- Industry
- Aerospace & Defense
- Address
- IPO Date
- Oct 3, 1990
- CIK
- 0000866121
- Similar Companies
- Business
- Orbital ATK Inc. (NYSE:OA) operates as an independent aerospace and defense manufacturer following its formation in 2015 from the merger of Orbital Sciences Corporation, founded in 1982, and Alliant Techsystems' aerospace and defense units; the company is headquartered in Dulles, Virginia. It designs, builds, and delivers a broad portfolio of products and services including launch vehicles such as Antares, Minotaur series, Pegasus, and the planned OmegA; solid rocket engines and boosters like GEM-40/60/63 series, Castor family, and Space Launch System boosters; satellites and spacecraft encompassing Cygnus cargo resupply vehicles for the International Space Station, communications satellites such as Al Yah 3 and HYLAS-4, and science missions including TESS, ICESat-2, and JPSS-2; tactical missiles, precision-guided munitions, ammunition, autocannons, firearms like the XM25 CDTE, and defense electronics including missile approach warning systems; as well as aerostructures, propulsion systems, and technical services for government, military, commercial, and scientific customers primarily in the United States with global operations. In a major strategic development, Northrop Grumman announced its $9.2 billion acquisition of Orbital ATK in September 2017, which closed on June 6, 2018, leading to the rebranding as Northrop Grumman Innovation Systems—a new business sector—before a 2020 reorganization integrated most operations into Northrop Grumman's Space Systems sector headquartered in McLean, Virginia; the company continues active trading under ticker OA with recent quarterly earnings reflecting EPS of $1.75 and revenue growth, alongside ongoing contributions to missile defense, space exploration, and aviation programs.
Eli Lilly's Retatrutide Shows Promising Results in Obesity and Osteoarthritis Trial
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs